Blinatumomab Benefit Assessment for ALL and Health Economics
The German Federal Joint Committee (G-BA) published a Blinatumomab benefit assessment under §35a SGB V. It evaluates its use as consolidation therapy in adults with newly diagnosed Philadelphia chromosome-negative (Ph−), CD19-positive B-cell precursor acute lymphoblastic leuk...
Enhertu Reimbursement Analysis: Navigating Cost-Effectiveness Challenges
The Dutch Healthcare Institute (ZIN) has recommended trastuzumab deruxtecan (Enhertu) for inclusion in the Netherlands’ basic insurance package for HER2-low metastatic breast cancer. This recommendation is contingent on a price reduction exceeding 68%. The DESTINY-Breast04 tr...
Global Drug Price Gaps Demand Better Drug Pricing Analysis
Introduction
For pharmaceutical executives steering pricing and strategy, understanding global drug price gaps is critical, especially as policies like the Most-Favored-Nation (MFN) pricing order (May 2025) loom. A 2024 RAND study reports U.S. prescription drug prices are 278% of those ...
NICE HealthTech Reforms: Accelerating Digital Innovation in NHS and Global Healthcare Systems
The National Institute for Health and Care Excellence (NICE) has unveiled sweeping reforms, termed NICE HealthTech Reforms, to accelerate digital health adoption in the NHS. These reforms shift from cost-saving to cost-effectiveness, merging three evaluation programmes into a unified HealthTech i...
BioNTech BMS Collaboration: Pioneering Advances in Solid Tumor Treatment with BNT327
BioNTech and Bristol-Myers Squibb (BMS) have entered a landmark partnership to co-develop and co-commercialize BNT327. This bispecific antibody targets PD-L1 and VEGF-A, aiming to advance clinical development across multiple solid tumors, including small cell lung cancer (SCLC), non-small cell lu...
Pluvicto Prostate Cancer Trial: Phase III Results
Novartis recently announced the topline results from the Phase III Pluvicto prostate cancer trial. The addition of Pluvicto™ (lutetium (177Lu) vipivotide tetraxetan) to standard hormone therapy significantly improved radiographic progression-free survival (rPFS) for patients with PSMA-positive me...
